BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34064761)

  • 21. KRas, ROS and the initiation of pancreatic cancer.
    Storz P
    Small GTPases; 2017 Jan; 8(1):38-42. PubMed ID: 27215184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
    Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF
    Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS: feeding pancreatic cancer proliferation.
    Bryant KL; Mancias JD; Kimmelman AC; Der CJ
    Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
    Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
    Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
    Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
    Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highlights on the Role of
    Hafezi S; Saber-Ayad M; Abdel-Rahman WM
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
    Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
    Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
    Ardito CM; GrĂ¼ner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT
    Cancer Cell; 2012 Sep; 22(3):304-17. PubMed ID: 22975374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
    Zhu Z; Xiao S; Hao H; Hou Q; Fu X
    Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells.
    Suzuki T; Kishikawa T; Sato T; Takeda N; Sugiura Y; Seimiya T; Sekiba K; Ohno M; Iwata T; Ishibashi R; Otsuka M; Koike K
    Cancer Gene Ther; 2022 May; 29(5):505-518. PubMed ID: 33833413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
    Lee JC; Shin J; Baek KH
    Biochem Biophys Res Commun; 2013 Oct; 440(1):50-5. PubMed ID: 24041692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.
    Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G
    Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality.
    Donahue TR; Dawson DW
    Trends Endocrinol Metab; 2016 Nov; 27(11):770-781. PubMed ID: 27461042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis.
    Nadella S; Burks J; Huber M; Wang J; Cao H; Kallakury B; Tucker RD; Boca SM; Jermusyck A; Collins I; Vietsch EE; Pierobon M; Hodge KA; Cui W; Amundadottir LT; Petricoin E; Shivapurkar N; Smith JP
    Pancreas; 2019 Aug; 48(7):894-903. PubMed ID: 31268978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.
    Hu CM; Tien SC; Hsieh PK; Jeng YM; Chang MC; Chang YT; Chen YJ; Chen YJ; Lee EYP; Lee WH
    Cell Metab; 2019 Jun; 29(6):1334-1349.e10. PubMed ID: 30853214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.
    Kent OA; Sandi MJ; Rottapel R
    Small GTPases; 2019 Nov; 10(6):441-448. PubMed ID: 28656876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.